Jefferies analyst Jeffrey Holford raised his price target for shares of Eli Lilly to $115 after upping his peak sales estimate for the Jardiance/Glyxambi franchise to $6B from $1.2B. Jardiance "missed" Street expectations yesterday of a 20% relative risk reduction on the primary composite outcome, but the 14% reduction in cardiovascular death or nonfatal stroke is still clinically relevant, Holford tells investors in a research note. The analyst expects the SGLT2 class will overtake, but not destroy, the DPP-IV class, with Eli Lilly as the leader. He keeps a Buy rating on the stock.